



11th of October Wednesday

17.00 - 19.30 **Opening Session: ICELAND MELANOMA DIAGNOSTICS, TREATMENT AND RESEARCH**

Session chair: Hildur Helgadóttir, Karolinska Institutet and Berglind Ósk Einarsdóttir, University of Iceland

17.00 *Welcome address*

Hildur Helgadóttir

17.15 *Icelandic research on melanoma epidemiology*

Laufey Tryggvadóttir, Icelandic Cancer Society

17.45 *Melanoma dermatology and dermatopathology in Iceland, UV-index, UV-beds*

Árni Kjalarr Kristjánsson, Landspítali University Hospital and Húðlæknastöðin

18.10 *Multidisciplinary melanoma team at Landspítali University Hospital*

Agnes Smáradóttir, Oncologist, Elísabet Reykdal, Dermatologist, Gunnar Auðólfsson, Plastic surgeon Landspítali University Hospital

18.35 *Insights into the E318K variant in MITF from a suppressor mutation in the mouse*

Eiríkur Steingrímsson, University of Iceland

19.05 *Population genetics in Iceland and skin cancer research by deCODE*

Simon Stacey, Project Leader, Oncology Division, deCODE Genetics

19:35- 21:00 **Opening ceremony and reception. Harpa Conference Center**

12th of October Thursday

8.25-10.05 **Session 1. Immunotherapy in melanoma**

Session chair: Berglind Ósk Einarsdóttir, University of Iceland and Henrik Jespersen, Oslo University Hospital

8.25 *Sequencing or combination of TT and IO in the treatment of melanoma*

Paolo Ascierto, National Tumor Institute Fondazione G. Pascale in Naples, Italy

8.50 *Adoptive T cell therapy for metastatic melanoma*
Inge Marie Svane, University of Copenhagen, Denmark

9.10 *Exploring the role of tertiary lymphoid structures in melanoma*
Göran Jönsson, Lund University, Sweden

Speakers chosen from abstracts

9.30 *Intratumoral immunostimulatory LOAd703 gene therapy combined with atezolizumab in advanced malignant melanoma patients; early results from the LOKON003 study*

Viktoria Rydén, Uppsala University Hospital, Sweden

9.42 *Radiotherapy for ICI-resistant melanoma: The PROMMEL study*
Muyi Yang, Karolinska Institutet, Stockholm, Sweden

9.54 *Neoadjuvant LTX-315 in combination with pembrolizumab in resectable stage III/IV melanoma (NeoLIPA trial): Protocol for a single center phase II open label study*

Henrik Jespersen, Oslo University Hospital, Norway

10.05 - 10.30 Coffee break

10.30 - 12.10 Session 2. Treatment of high-risk melanoma

Session chair: Tina Hieken, Mayo Clinic, USA and Oxford and Micaela Hernberg, University of Helsinki

10.30 *Changing paradigms and open questions for adjuvant therapy of high-risk early-stage melanoma* Jason Luke, University of Pittsburgh, USA

10.55 *The next steps to full personalization of neoadjuvant melanoma therapy*
Christian Blank, The Netherlands Cancer Institute, Amsterdam, Netherlands

Speakers chosen from abstracts

11.20 *Overall Survival After the Introduction of Adjuvant Treatment in Stage III Melanoma: A Nationwide Registry Based Study*
Hildur Helgadóttir, Karolinska University Hospital, Stockholm, Sweden

11.32 *Minimal Invasive Limb Perfusion (MI-ILP)*
Anne Huibers, Sahlgrenska University Hospital

11.44 *A role for pelvic sentinel lymph nodes in lower extremity melanoma*
Henrik Nuutinen, Kuopio University Hospital/University of Eastern Finland

11.56 *Survival in cutaneous head and neck melanoma is affected by a non-radical primary diagnostic biopsy*

Anna Hafstrom, Skåne University Hospital, Lund, Sweden

12.10 - 13.05 Lunch

13.05 – 15.00 Session 3. Signaling in melanoma

Session chair: Eiríkur Steingrímsson and Lionel Larue, Institut Curie, Paris, France

13.10 *What makes a melanocyte competent to become a melanoma?*

Richard White, Memorial Sloan Kettering Cancer Center, NY, USA and the University of Oxford, UK

13.35 *Biomarkers of AXL signaling in melanoma, experience from clinical trial BGBIL006 (NCT02872259)*

Oddbjørn Straume, University of Bergen, Norway

Speakers chosen from abstracts

13.55 *BRN2 acts as a guardian of melanocyte stem cells and as a non-classical tumor suppressor*

Lionel LARUE, Institut Curie, France

14.10 *Melanoma dedifferentiation and immune evasion*

Berglind Ósk Einarsdóttir, Department of Medicine, University of Iceland

14.22 *EGLN1 is a druggable dependency in neural crest-like melanoma*

Martin Qvist Rasmussen, Department of Biomedicine, Aarhus University

14.34 *Mechanistic basis of atypical TERT promoter mutations in melanoma*

Kerryn Elliott, The Sahlgrenska Academy, University of Gothenburg, Sweden

14.46 *MITF represses the expression of the receptor-ligand pair VEGFA and FLT1*

Seyedeh Parinaz Mahdavi, Department of Biochemistry and BioMedical Center, Faculty of Medicine, University of Iceland

15.00 - 15.30 Coffee break

15.30 - 17.10 Session 4. Management and outcome in resectable melanoma

Session chair: Susana Puig, University of Barcelona, Spain and Laufey Tryggvadóttir, Icelandic Cancer Society

15.30 *SLN Surgery and Neoadjuvant Therapy: A Surgeon's Perspective*

Tina Hieken, Mayo Clinic, USA

Speakers chosen from abstracts

15.55 *Teledermatoscopy in the Stockholm region, Sweden: Improved Lead Times for Melanoma Care*

Karina Schultz, Karolinska University Hospital, Stockholm, Sweden

- 16.07 *The use of RCM in detection of local recurrence of Lentigo maligna melanoma (LMM)*
Ada Girnita, Karolinska University Hospital, Stockholm, Sweden
- 16.19 *Trial to assess the Role of Imaging during follow up after radical surgery of stage IIb-c and III cutaneous malignant Melanoma (TRIM) – an interim analysis*
Ylva Naeser, Uppsala University, Uppsala University Hospital, Sweden
- 16.31 *Recurrence and mortality in melanoma Stage-specific risks and the role of routine FDG PET-CT in surveillance*
Neel Maria Helvind, Copenhagen University Hospital: Herlev and Gentofte, Denmark
- 16.43 *Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - a tool for individualised treatment decisions*
Karolin Isaksson, Lund University, Lund, Kristianstad Hospital, Kristianstad, Sweden
- 16.55 *Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden*
Sofi Vikström, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

19.00 - 23.00 Conference dinner in Harpa (Norðurljós)*

*This dinner is optional and not included in the registration fee

13th of October Friday

8.30-10.10 Session 1. Melanoma in different subgroups, biomarkers

Session chair: Richard White, Memorial Sloan Kettering and Inge-Marie Svane, Copenhagen University

- 8.30 *Implementation of biomarkers in melanoma*
Susana Puig, University of Barcelona, Spain
- 8.55 *The E-cadherin-ESR1-GRPR axis defines a sex-specific metastatic pathway in melanoma*
Veronique Delmas, Institut Curie, Paris, France
- Speakers chosen from abstracts***
- 9.20 *Perioperative examination of inflammatory markers in relation to sentinel lymph node biopsy in patients with melanoma; a pilot study*
Karoline A. Kristjansen, Aalborg University Hospital, Denmark
- 9.32 *Treatment strategies and outcome for a nationwide cohort of real-world patients with melanoma brain metastases and meningeal carcinosis, and benefit of postoperative stereotactic radiotherapy*
Sidsel Pedersen, Herlev and Gentofte Hospital, Denmark

9.44 *Patient Perspectives on Diagnosing and Treatment of Stage III and IV Melanoma — A Nordic Patient Survey*
Henrik Jespersen, Oslo University Hospital, Radiumhospitalet, Norway

9.55- 10.05 Information about ACTA Oncologica

Micaela Hernberg, University of Helsinki, Editor ACTA Oncologica

10.05 - 10.40 Coffee break

10.40 - 12.15 Session 2. Uveal and cutaneous melanoma: Prognosis and predictive markers

Session chair: Göran Jönsson and Jason Luke University of Pittsburgh, USA

10.45 *Immunotherapy in metastatic uveal melanoma: checkpoint inhibition and beyond*
Lars Ny, University of Gothenburg, Sweden

11.05 *Regional treatment for patients with uveal melanoma liver metastases*
Roger Olofsson Bagge, University of Gothenburg, Sweden

Speakers chosen from abstracts

11.25 *Investigation of predictive markers in melanoma patients treated with Ipilimumab*
Cornelia Schuster, University of Bergen, Haukeland University Hospital, Bergen, Norway

11.37 *The tumor microenvironment may have an influence on isolated limb perfusion treatment outcome in locally advanced melanoma*
Sanni Tulokas, Helsinki University Hospital, Finland

11.49 *Using a clinicopathologic and gene expression model to predict sentinel lymph node metastasis in primary cutaneous melanoma could reduce the rate of sentinel lymph node biopsies with >70% in thin melanoma: a multicentre Danish cohort study*
Marie Brinch-Møller Weitemeyer, Copenhagen University Hospital, Herlev and Gentofte, Denmark

12.01 *Inflammation-related proteins associated with worse clinical outcome in melanoma patients treated with immune checkpoint inhibitors*
Suzanne Egyhazi Brage, Karolinska Institutet, Stockholm, Sweden

12.15 - 13.25 Lunch

13.25 - 14.50 Session 3. Real-world data and side effects of melanoma treatments

Session chair: Max Levin, University of Gothenburg and Paolo Ascierto, National Tumour Institute, Naples, Italy

13.30 *Choosing systemic treatment for older patients with metastatic melanoma*

Siru Mäkelä, University of Helsinki, Finland

Speakers chosen from abstracts

13.50 *Checkpoint inhibitor-induced adverse events in the CNS – T cell characteristics and biomarkers*

Sara Bjursten, Sahlgrenska Academy, University of Gothenburg, Sweden

14.02 *A potential role of antigen-presenting non-classical monocytes in mediating exceptional response in checkpoint inhibitor-induced sarcoidosis*

Ankur Pandita, Sahlgrenska University Hospital, Gothenburg, Sweden

14.14 *Gender differences in outcomes and side effects of immune checkpoint inhibitors in Cancer*

Johan Franzén, Karolinska Institutet, Stockholm, Sweden

14.26 *Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome*

Eva Ellebaek, Copenhagen University Hospital, Herlev and Gentofte, Denmark

14.38 *Real-world data for dabrafenib and trametinib combination therapy in patients with advanced malignant melanoma: the PRODAT non-interventional prospective multicenter study*

Simen Myhre, Novartis Norway

14.50 - 15.20 Coffee break

15.20 - 16.50 Session 4. Burning clinical questions (discussion/panel with international experts)

Session chair: Hildur Helgadóttir, Karolinska Institutet and Gustav Ullenhag, University of Uppsala

Jason Luke, University of Pittsburgh, USA

Paolo Ascierto, National Tumour Institute, Naples, Italy

Christian Blank, The Netherlands Cancer Institute, Amsterdam

Tina Hieken, Mayo Clinic, USA

Susana Puig, University of Barcelona, Spain

16:50-17:00 Closing remarks. Eiríkur Steingrímsson, University of Iceland

17:30-19:00 Meeting of the Nordic Melanoma Group Steering Committee (closed meeting)